Bridgehead International Provides Due Diligence for Investinor AS
News Feb 24, 2012
BerGenBio AS has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors in the raise were Sarsia Seed AS and Investinor AS.
Bridgehead International was appointed by Investinor AS, the Government of Norway venture capital investment corporation, to carry out a due diligence study on BerGenBio AS.
This covered the main technical and commercial elements of the company’s programmes, its business plans and the capacity of the management team to deliver.
Bridgehead’s CEO, Timothy Fitzgerald, commented: ‘Bridgehead’s expert team was able to provide a rapid, in depth assessment of the BerGenBio portfolio, and to assess this leading edge science in a clear commercial context. It is very satisfying to see that our advisory work has contributed to this investment round and we wish the company and its investors every success for the future’.
Jon Øyvind Eriksen of Investinor said: ‘By examining BerGenBio’s main value drivers and evaluating the current status of the company’s programmes, Bridgehead’s consultants provided Investinor with excellent advice which both confirmed our investment thesis. and identified opportunities for Investinor to add value to the company as active owners’.
Tailor-made Protein Fights Several Species of BacteriaNews
As resistance to existing antibiotics increases, new approaches to serious bacterial infections are needed. Now researchers have investigated one such alternative.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE